Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Rhea-AI Summary
Anteris Technologies Global Corp (NASDAQ: AVR) announced the closing of a public offering of 40,000,000 common shares and a private placement of 15,652,173 shares to Medtronic, each at $5.75 per share. Gross proceeds from both transactions were approximately $320 million before fees and expenses. Underwriters included Barclays, Wells Fargo Securities and Cantor; Wells Fargo acted as placement agent for the Medtronic sale. The company said net proceeds will fund the global pivotal PARADIGM Trial for the DurAVR THV, expand manufacturing, support R&D for v2vmedtech, and for working capital and general corporate purposes.
Positive
- Gross proceeds of approximately $320 million
- 40,000,000 shares sold in the public offering at $5.75
- 15,652,173 shares sold to Medtronic at $5.75
- Proceeds earmarked to fund the PARADIGM pivotal trial for DurAVR THV
Negative
- Issuance of 55,652,173 new shares may dilute existing shareholders
- Net proceeds reduced by underwriting discounts, placement fees and expenses
News Market Reaction
On the day this news was published, AVR declined 1.67%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.3% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $278M at that time. Trading volume was exceptionally heavy at 13.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AVR was up 5.39% while peers showed small mixed moves: KRMD +1.79%, INFU +1.89%, UTMD +1.32%, offset by MBOT -4.04% and NYXH -1.04%, pointing to a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Equity offering priced | Negative | +12.5% | Pricing of $200M equity offering with Medtronic-linked private placement. |
| Jan 20 | Offering proposed | Negative | +12.5% | Proposed $200M offering plus up to $90M strategic Medtronic investment. |
| Nov 17 | Clinical data update | Positive | -3.3% | Strong 30‑day outcomes in 100 DurAVR THV patients at PCR London Valves. |
| Nov 12 | Q3 2025 results | Negative | -2.6% | High cash burn and low cash balance alongside PARADIGM trial investments. |
| Nov 03 | FDA trial approval | Positive | -3.1% | FDA IDE approval to initiate PARADIGM pivotal trial for DurAVR THV. |
Recent news often produced price moves that diverged from the intuitive sentiment, including positive reactions to dilutive offerings and occasional pullbacks on strong clinical or regulatory milestones.
Over the past few months, Anteris reported key milestones around its DurAVR® THV program and financing strategy. An FDA approval on Nov 3, 2025 for the PARADIGM pivotal trial and strong 100‑patient data on Nov 17, 2025 were followed by modest share price declines. Q3 2025 results highlighted significant cash burn and low cash of $9.1M. More recently, the company announced a proposed and then priced equity offering with a Medtronic-linked investment on Jan 20, 2026, which coincided with a 12.52% gain, showing investor appetite for the capital raise despite dilution.
Market Pulse Summary
This announcement confirms the closing of a sizeable equity raise: 40,000,000 shares in a public offering and 15,652,173 shares in a Medtronic-related private placement at $5.75 per share, for about $320M in gross proceeds. Context from recent filings shows these funds targeted to the PARADIGM pivotal trial, DurAVR® THV manufacturing expansion, and R&D, including v2vmedtech. Investors may watch execution of trial milestones, manufacturing scale-up, and future capital needs given the company’s development-stage status and prior going‑concern language.
Key Terms
underwritten public offering financial
private placement financial
prospectus supplement regulatory
Securities Act regulatory
stabilizing actions technical
AI-generated analysis. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase additional shares from the Company (the “Shares”). The Shares were sold at a public offering price of
In addition, Anteris today announced the closing of its previously announced sale, in a private placement (the “Private Placement”), of 15,652,173 shares of common stock to Medtronic plc (through a wholly owned subsidiary) at a price of
The gross proceeds to the Company from the Offering and the Private Placement were approximately
Barclays, Wells Fargo Securities and Cantor acted as joint book-running managers for the Offering. Barrenjoey Markets Pty Limited acted as financial advisor in connection with the Offering to investors in Asia-Pacific and certain other jurisdictions outside of the United States and Canada. Wells Fargo Securities acted as sole placement agent in connection with the private placement of Anteris’ shares to Medtronic.
Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth and advance execution of the Company’s clinical strategy. This includes ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (“DurAVR® THV”) global pivotal trial for patients with severe aortic stenosis (the “PARADIGM Trial”) and expansion of manufacturing capabilities. In addition, a portion of the proceeds is expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes determined from time to time.
The Offering was made pursuant to a shelf registration statement on Form S-3 (the “Form S-3 Registration Statement”) that was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on January 8, 2026. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at barclaysprospectus@broadridge.com; Wells Fargo Securities, LLC, 90 South 7th Street, Minneapolis, MN 55402, by telephone at (800) 645-3751 (option #5), or by email at WFScustomerservice@wellsfargo.com; or Cantor Fitzgerald & Co., by mail at Attention: Capital Markets, 110 East 59th Street, New York, NY 10022, or by email at prospectus@cantor.com.
The shares of common stock offered and sold in the Private Placement have not been registered under the Securities Act or any state’s securities laws. Accordingly, such securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. The prospectus supplement and the accompanying prospectus related to the Offering are not an offer to sell or a solicitation of an offer to buy any securities in connection with the Private Placement.
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the final prospectus supplement related to the Offering, the underwriters may engage in stabilizing actions or related activities in connection with the Offering.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. The safety and efficacy of the DurAVR® THV are being evaluated in the PARADIGM Trial (NCT07194265), with the first patients enrolled and implanted with the DurAVR® THV in Denmark during the fourth quarter of 2025.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the anticipated use of the net proceeds of the Offering and the Private Placement and that the underwriters may engage in stabilizing actions or related activities in connection with the Offering. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in the Form S-3 Registration Statement and the final prospectus supplement and accompanying prospectus related to the Offering. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | |
| Investor Relations investors@anteristech.com Debbie Ormsby Anteris Technologies Global Corp. +61 1300 550 310 | +61 7 3152 3200 | Investor Relations (US) mchatterjee@bplifescience.com Malini Chatterjee, Ph.D. Blueprint Life Science Group +1 917 330 4269 |
FAQ
How many shares did Anteris (AVR) issue in the January 22, 2026 offering and private placement?
What price per share did Anteris (AVR) receive in the January 22, 2026 transactions?
How much gross capital did Anteris (AVR) raise on January 22, 2026?
What will Anteris (AVR) use the offering proceeds for?
Did a strategic investor participate in Anteris (AVR)'s January 22, 2026 financings?
Who were the lead underwriters for Anteris (AVR)'s public offering?
